Hana Pharm Co., Ltd. (293480.KS)
KRW 10850.0
(-0.73%)
KRW 10850.0
(-0.73%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 35.48 Billion KRW | -13.25% |
| 2022 | 37.73 Billion KRW | -6.86% |
| 2021 | 41.65 Billion KRW | 25.43% |
| 2020 | 33.54 Billion KRW | -16.22% |
| 2019 | 39.11 Billion KRW | 5.86% |
| 2018 | 37.5 Billion KRW | 5.74% |
| 2017 | 35.33 Billion KRW | 30.26% |
| 2016 | 27.34 Billion KRW | 40.78% |
| 2015 | 17.76 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 9.59 Billion KRW | 11.47% |
| 2024 Q2 | -115.01 Billion KRW | -22.78% |
| 2023 Q3 | 34.3 Billion KRW | -5.33% |
| 2023 Q4 | 7.73 Billion KRW | -77.45% |
| 2023 Q1 | 33.98 Billion KRW | 228.44% |
| 2023 Q2 | 36.23 Billion KRW | 6.61% |
| 2023 FY | - KRW | -13.25% |
| 2022 FY | - KRW | -6.86% |
| 2022 Q4 | 10.34 Billion KRW | 11.35% |
| 2022 Q3 | 9.29 Billion KRW | -1.91% |
| 2022 Q2 | 9.47 Billion KRW | -2.74% |
| 2022 Q1 | 9.74 Billion KRW | -22.49% |
| 2021 FY | - KRW | 25.43% |
| 2021 Q2 | 11.83 Billion KRW | 59.6% |
| 2021 Q1 | 7.41 Billion KRW | 28.63% |
| 2021 Q4 | 12.56 Billion KRW | 26.98% |
| 2021 Q3 | 9.89 Billion KRW | -16.38% |
| 2020 Q3 | 10.99 Billion KRW | 45.38% |
| 2020 Q2 | 7.56 Billion KRW | -11.68% |
| 2020 FY | - KRW | -16.22% |
| 2020 Q1 | 8.56 Billion KRW | -20.19% |
| 2020 Q4 | 5.76 Billion KRW | -47.55% |
| 2019 Q1 | 9.45 Billion KRW | -14.19% |
| 2019 FY | - KRW | 5.86% |
| 2019 Q4 | 10.72 Billion KRW | 1.01% |
| 2019 Q3 | 10.62 Billion KRW | 19.34% |
| 2019 Q2 | 8.89 Billion KRW | -5.86% |
| 2018 Q3 | 9.86 Billion KRW | 18.39% |
| 2018 Q1 | 8.17 Billion KRW | 0.0% |
| 2018 FY | - KRW | 5.74% |
| 2018 Q4 | 11.01 Billion KRW | 11.68% |
| 2018 Q2 | 8.33 Billion KRW | 1.93% |
| 2017 FY | - KRW | 30.26% |
| 2017 Q3 | 10.33 Billion KRW | 0.0% |
| 2016 FY | - KRW | 40.78% |
| 2015 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -630.423% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 74.897% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 155.416% |
| HANDOK Inc. | 35.06 Billion KRW | -1.197% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 3523.428% |
| Yuhan Corporation | 127.43 Billion KRW | 72.153% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 5.423% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 263.626% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 89.025% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -611.104% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -134.726% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -937.318% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -683.987% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -630.423% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 292.111% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -441.367% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 171.992% |
| JW Holdings Corporation | 187.88 Billion KRW | 81.113% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 169.271% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 87.488% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 60.226% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 195.736% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -168.641% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -200.024% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -90.226% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -630.423% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 35.448% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 78.482% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 60.226% |
| Yuhan Corporation | 127.43 Billion KRW | 72.153% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -6.006% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -363.885% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 53.931% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 60.226% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 3.134% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 49.864% |
| CKD Bio Corp. | -1.63 Billion KRW | 2276.488% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 28.732% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -8.983% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 3.597% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 195.736% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 43.025% |
| Boryung Corporation | 114.28 Billion KRW | 68.95% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 216.089% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -134.726% |
| JW Lifescience Corporation | 50.82 Billion KRW | 30.185% |